Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Insight Molecular Diagnostics's Debt-to-Equity or its related term are showing as below:
IMDX'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.34 Med: 0.1 Max: 3.07
Current: -0.29
During the past 13 years, the highest Debt-to-Equity Ratio of Insight Molecular Diagnostics was 3.07. The lowest was -0.34. And the median was 0.10.
IMDX's Debt-to-Equity is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 0.33
vs IMDX: -0.29
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Insight Molecular Diagnostics Debt-to-Equity Related Terms
Insight Molecular Diagnostics Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insight Molecular Diagnostics Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Insight Molecular Diagnostics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insight Molecular Diagnostics (IMDX) has a Debt-to-Equity of -0.29 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Insight Molecular Diagnostics and its competitors. According to the industry distribution chart, Insight Molecular Diagnostics ranks #999999 out of 183 companies in the Medical Diagnostics & Research industry.
Is Insight Molecular Diagnostics' Debt-to-Equity too high?
Insight Molecular Diagnostics' current Debt-to-Equity is -0.29. Based on the distribution chart, Insight Molecular Diagnostics ranks #999999 out of 183 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' Debt-to-Equity compare to XGN and BDSX?
According to the Medical Diagnostics & Research industry distribution chart, Insight Molecular Diagnostics ranks #999999 out of 183 companies for Debt-to-Equity. This places Insight Molecular Diagnostics in the lower half of its industry. The industry median Debt-to-Equity is 0.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.33, based on 183 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Insight Molecular Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Insight Molecular Diagnostics's current Debt-to-Equity is -0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Insight Molecular Diagnostics (IMDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.25, compared to a current price of $4.68 — trading 274.4% above its estimated fair value. The current Debt-to-Equity is -0.29. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Insight Molecular Diagnostics (IMDX), the current Debt-to-Equity is -0.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?
Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued.
The current stock price of $4.68 is trading 274.4% above its estimated GF Value™ of $1.25.
GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.
Key valuation signals for IMDX:
Debt-to-Equity: -0.29
GF Value™: $1.25 vs. price of $4.68 (274.4% above fair value)
No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insight Molecular Diagnostics Business Description
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score
Get the complete analysis for IMDX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMDX has been successfully added to your 
